title: Rituximab improved systemic lupus erythematosus-associated pulmonary alveolar proteinosis without decreasing anti-GM-CSF antibody levels.
authors: Clinical Immunology, Dokkyo Medical University, Tochigi, Japan Department of Rheumatology, Kamitsuga General Hospital, Tochigi, Japan.
authors: J
authors: J
authors: Nagasawa
authors: Clinical Immunology, Dokkyo Medical University, Tochigi, Japan kurasawa@dokkyomed.ac.jp.
authors: K
authors: K
authors: Kurasawa
authors: Department of Rheumatology, Kamitsuga General Hospital, Tochigi, Japan.
authors: R
authors: R
authors: Hanaoka
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D011649:Pulmonary Alveolar Proteinosis / Q000188:drug therapy*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D001323:Autoantibodies; D007155:Immunologic Factors; D000069283:Rituximab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor